Stephen Black (London, UK) talks to VEITHtv about how the dedicated venous open-cell nitinol Abre stent (Medtronic) compares with other venous nitinol stents available, noting that it is very easy to use, has good flexibility attributes and a “good range of sizes and lengths”. He maintains that Abre is a rounded effective option for the treatment of the majority of patients presenting with deep venous disease and that it looks likely to be particularly advantageous under the inguinal ligament.
Black discusses the demographic data from the Abre study, presented at VEITH 2019 (19–23 November, New York, USA), which notably included patients across all broad groups that are regularly treated, including those with acute deep venous thrombosis (DVT), non-thrombotic iliac vein lesions (NIVL) and those with post-thrombotic syndrome. He further outlines plans to release the Abre study 12-month follow-up results at the Charing Cross Symposium 2020.
This video is sponsored by Medtronic.